Abstract
More and more evidences are still accumulating rapidly on the G-protein-coupled-receptors (GPCRs) dimerization/ oligomerization. Such common feature of GPCRs has called extensive attention to both pharmacologists and medicinal chemists for illustration of the pharmacological functions and therapeutic utilities of such receptor complex. Although there is still no clear explanation for the receptor dimerization/oligomerization, a large number of multivalent ligands (MLs) have been designed to target the receptor-dimers/oligomers. Such MLs have gained much acceptance in exploring the receptor complex of dopaminergic, adrenergic, serotoninergic, and opioidic receptor systems, due to the relatively broader experience in recognizing the receptor-dimerization. More and more MLs have also been designed to face GPCRrelated very complex neurodegenerative diseases, such as Parkinsons disease (PD), Alzheimers disease (AD) and schizophrenia, which are not effectively treated by traditional highly selective drugs. Herein, some of the most recent developments in this field, as well as some typical examples of MLs, are highlighted, with a particular focus on GPCRs.
Keywords: Multivalent ligand, G-protein-coupled receptors (GPCRs), drug design and development, heterodimerization, Parkinson's disease, Alzheimer's disease, schizophrenia, drug abuse, drug target
Current Pharmaceutical Design
Title: Design of Multivalent Ligand Targeting G-Protein-Coupled Receptors
Volume: 15 Issue: 6
Author(s): Zhili Liu, Jing Zhang and Ao Zhang
Affiliation:
Keywords: Multivalent ligand, G-protein-coupled receptors (GPCRs), drug design and development, heterodimerization, Parkinson's disease, Alzheimer's disease, schizophrenia, drug abuse, drug target
Abstract: More and more evidences are still accumulating rapidly on the G-protein-coupled-receptors (GPCRs) dimerization/ oligomerization. Such common feature of GPCRs has called extensive attention to both pharmacologists and medicinal chemists for illustration of the pharmacological functions and therapeutic utilities of such receptor complex. Although there is still no clear explanation for the receptor dimerization/oligomerization, a large number of multivalent ligands (MLs) have been designed to target the receptor-dimers/oligomers. Such MLs have gained much acceptance in exploring the receptor complex of dopaminergic, adrenergic, serotoninergic, and opioidic receptor systems, due to the relatively broader experience in recognizing the receptor-dimerization. More and more MLs have also been designed to face GPCRrelated very complex neurodegenerative diseases, such as Parkinsons disease (PD), Alzheimers disease (AD) and schizophrenia, which are not effectively treated by traditional highly selective drugs. Herein, some of the most recent developments in this field, as well as some typical examples of MLs, are highlighted, with a particular focus on GPCRs.
Export Options
About this article
Cite this article as:
Liu Zhili, Zhang Jing and Zhang Ao, Design of Multivalent Ligand Targeting G-Protein-Coupled Receptors, Current Pharmaceutical Design 2009; 15 (6) . https://dx.doi.org/10.2174/138161209787315639
DOI https://dx.doi.org/10.2174/138161209787315639 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design Smoking and Weight
Current Respiratory Medicine Reviews Increasing Expression of Heme Oxygenase-1 by Proteasome Inhibition Protects Astrocytes from Heme-mediated Oxidative Injury
Current Neurovascular Research Daunorubicin Metabolism in Leukemic Cells Isolated from Patients with Acute Myeloid Leukemia
Drug Metabolism Letters Flow Volumes of Internal Jugular Veins are Significantly Reduced in Patients with Cerebral Venous Sinus Thrombosis
Current Neurovascular Research Efficient In Vitro Refolding and Characterization of a New Peptide from the Scorpion Buthotus saulcyi Venom Produced in Escherichia coli
Protein & Peptide Letters Compromise and Care of the Brains Compartments: The Quintessence of the Neurovascular Unit
Current Neurovascular Research Cigarette Smoking is Associated with Decreased Bone Gla-protein (BGP) Levels in Hemodialysis Patients
Current Vascular Pharmacology Neuropathic Pain: Models and Mechanisms
Current Pharmaceutical Design Relationship Between Virulence Factors and Outcome of Ventilator-Associated Pneumonia Related to Pseudomonas aeruginosa
Current Respiratory Medicine Reviews Neuroprotective Effects of Lithium in Patients with Bipolar Disorder
Current Psychopharmacology Recent Patents on Active Self-Ligating Brackets for Orthodontic Treatment
Recent Patents on Mechanical Engineering Oxidative Stress During Myocardial Ischaemia and Heart Failure
Current Pharmaceutical Design Methionine-Independent Translation Initiation from Naturally Occurring Non-AUG Codons
Current Chemical Biology Mechanisms in the Development of Multiple Sclerosis Lesions: Reconciling Autoimmune and Neurodegenerative Factors
CNS & Neurological Disorders - Drug Targets Anorexia of Aging
Current Nutrition & Food Science A Role for Glutathione in the Pathophysiology of Bipolar Disorder and Schizophrenia? Animal Models and Relevance to Clinical Practice
Current Medicinal Chemistry Catastrophic Antiphospholipid Syndrome: Lessons from the “CAPS Registry”
Current Rheumatology Reviews Current Perspectives for the use of Gonane Progesteronergic Drugs in the Treatment of Central Hypoventilation Syndromes
Current Neuropharmacology